Starbucks (SBUX) Has Room to Run, Goldman Sachs Says; PT Lifted to $57
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pre-Open Stock Movers 04/24: (AMZN) (MSFT) (GOOG) (SBUX) Higher; (AERI) (AMSC) (STEM) (DDD) Lower (more...)
April 24, 2015 9:32 AM EDTAerie Pharmaceuticals, Inc. (NASDAQ: AERI) 55.5% LOWER; reported the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma. However, RhopressaTM demonstrated non-inferiority compared to... More
Starbucks (SBUX) PT Lifted 10% at RBC Capital Following Strong Q2
April 24, 2015 6:32 AM EDTRBC Capital analyst David Palmer reiterated an Outperform rating and boosted his price target on Starbucks (NASDAQ: SBUX) to $55.00 (from $50.00) following Q2 results on higher sales momentum, productivity, and benign costs.
"We believe investments in innovation, technology, and brand development will fuel... More
After-Hours Stock Movers 04/23: (AMZN) (JNPR) (SBUX) (GOOG) (MSFT) Higher; (AERI) (UBNT) (AWAY) Lower (more...)
April 23, 2015 6:04 PM EDTAerie Pharmaceuticals, Inc. (NASDAQ: AERI) 69.5% LOWER; reported the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma. However, RhopressaTM demonstrated non-inferiority compared to timolol for patients in the study with IOP below 26... More
Starbucks Coffee (SBUX) Reports In-Line Q2 EPS, Reaffirms FY EPS Guidance
April 23, 2015 4:05 PM EDT(Updated - April 23, 2015 4:07 PM EDT)
Starbucks Coffee (NASDAQ: SBUX) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.53 billion. Global comparable store sales increased 7%, with a 3% increase in traffic.
Starbucks record financial and operating performance in Q2 was driven by our people all around the... More
